News
Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA.
Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...
News-Medical.Net on MSN4d
Drug combination shows promise for treating aggressive T-cell lymphomasRelapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...
Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...
Carrie Kitko, MD, explains that axatilimab maintains strong response rates in patients with chronic graft-versus-host disease (GVHD) regardless of previous treatment lines and emphasizes the need to ...
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback